- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03725085
Study to Evaluate the Safety and Tolerability of Mucinex™(Guaifenesin) 600 mg Extended-Release Bi-Layer Tablets in the Treatment of Otherwise Healthy Patients With Symptoms of Cough, Thickened Mucus and Chest Congestion
An Open Label, Multicentric Study to Evaluate the Safety and Tolerability of Mucinex™(Guaifenesin) 600 mg Extended-Release Bi- Layer Tablets in the Treatment of Otherwise Healthy Patients With Symptoms of Cough, Thickened Mucus and Chest Congestion
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients were eligible for enrolment in the study if they fulfilled the following criteria:
- Males and females (non-pregnant) patients of ≥ 18 years of age.
Otherwise healthy patients suffering from cough with symptoms of thickened mucus and chest congestion and a diagnosis of any one of the following:
- Acute Bronchitis
- Upper Respiratory Tract Infections (URTI) such as naso-pharyngitis
- Sinusitis
Females of child bearing potential:
- Must have used efficacious and reliable method of contraception during the entire duration of the study {e.g. double barrier methods (e.g., condom and spermicidal); intrauterine device (IUD) } or remained sexually inactive throughout the study*.
- Must have had a negative urine pregnancy test (UPT) at Screening/Baseline (test must have a sensitivity of at least 25 mIU/mL for HCG).
- Must have been non-lactating.
- Patients must have demonstrated their willingness to participate in the study and comply with the study procedures and required visits.
- Patients must have been willing to authorize use and disclosure of protected health information collected for the study.
Patients must have had the ability to understand and sign a written consent, which had to be signed prior to study specific procedures being performed.
- *Abstinence (sexually inactive) was not an acceptable form of contraception; however, abstinent female patients could have been admitted to the study if they agreed, and signed a statement to the effect, that upon becoming sexually active, they would use a condom with spermicide from that time through 30 days beyond completion of the study (Visit 2).
Exclusion Criteria:
Patients were excluded from the study if they fulfilled any of the following:
- Females who were pregnant or lactating or planning to become pregnant during the study period.
- Patients with a history of chronic cough of > 3 weeks duration.
Patients with any of the following conditions:
- Asthma
- Chronic bronchitis
- Emphysema
- Other chronic pulmonary conditions such as Chronic Obstructive Pulmonary Disease (COPD) or cystic fibrosis (CF), etc.
- Patients with known hypersensitivity to GGE.
- Patients with temperature greater than 101°F (38.3°C) at Screening/Baseline.
- Patients with a serious and/or uncontrolled medical condition (chronic or active liver disease, renal impairment, heart disease, diabetes, severe respiratory disease, rheumatoid arthritis, current malignancies, immunocompromised conditions or any other disease) that in the opinion of the investigator would interfere with the study or place the patient at unacceptable risk.
- Patients with a history or examination findings of alcohol dependence, alcohol or drug abuse or suspected abuse within the past 2 years.
- Patients who had participated in a study of an investigational drug within 30 days prior to the Screening/Baseline visit.
- Patients who in the opinion of the investigator were unable to comply fully with the study requirements.
- Related to persons involved directly or indirectly with the conduct of this study [i.e., investigator, sub-investigators, study coordinators, other study personnel, employees of Reckitt Benckiser or Ecron AcuNova Ltd. (EAL), formerly known as Manipal Acunova Limited (MAL) and the families of each].
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mucinex™ (GGE, 600 mg extended-release bi-layer tablets)
2 tablets of Mucinex™ (GGE, 600 mg ER bi-layer tablets, taken as 1200 mg BID dose) every 12 hours (twice daily, in the morning and the evening) orally with a full glass of water for 7 days. GGE = Guaifenesin BID = Twice in a day |
2 tablets of Mucinex™ (GGE, 600 mg extended-release bi-layer tablets)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Adverse Events (AEs), Type of AE(s) and Frequency of AE(s)
Time Frame: Up to Day 9
|
Treatment Emergent Adverse Event (TEAE) are events occurring after the first dose of study medication. Frequency of AE(s) - the total Number of Events Type of AE(s) - Serious TEAE and Non serious TEAE |
Up to Day 9
|
Number of Subjects Affected With Adverse Events
Time Frame: Up to Day 9
|
Proportion of patients with AE(s) - Number of Subjects affected with Events
|
Up to Day 9
|
Number of Adverse Events by Severity, Seriousness and the Relationship of AE(s) to Treatment
Time Frame: Up to Day 9
|
Intensity determined. Mild = AE did not limit usual activities; subject may have experienced slight discomfort. Moderate = AE resulted in some limitation of usual activities; subject may have experienced significant discomfort. Severe = AE resulted in an inability to carry out usual activities; subject may have experienced intolerable discomfort/pain. Relationship to Investigational Medicinal Products (IMP) Unassessable/Unclassified = Insufficient information to be able to make an assessment Conditional/ Unclassified = Insufficient information to make an assessment at present Unrelated = No possibility that the AE was caused by the IMP Unlikely = Slight, but remote, chance that the AE was caused by the IMP, but the balance of judgment was that it was most likely not due to the IMP. Possible = Reasonable suspicion that the AE was caused by the IMP Probable = Most likely that the AE was caused by the IMP Certain = AE was definitely caused by the IMP |
Up to Day 9
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Assessment of the Study Medication by End of Study Patient Questionnaire
Time Frame: Up to Day 9
|
End of Study Patient Questionnaire is a questionnaire provided to the patients for overall assessment of the study medication at the end of study visit. Satisfied(stfd) Dissatisfied(Dstfd) |
Up to Day 9
|
Overall Assessment of the Study Medication by End of Study Investigator Questionnaire
Time Frame: Up to Day 9
|
End of Study Investigator Questionnaire is a questionnaire provided at the end of study visit to the investigator (or sub-investigator as applicable) for overall assessment of the study medication across all patients treated by them. End of study investigator questionnaire was collected from 9 investigators. Mostly Satisfied(MS) Satisfied(Stfd) Very Satisfied(VS) Chest Congestion(CC) Chesty Cough(CCO) Difference(Diff) Between(b/w) Somewhat Agree(SA) Strongly Agree(StA) Upper respiratory tract infection(URTI) Optimal dosage(Opt dos) Cough preparations Available(CPA) |
Up to Day 9
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012-MUC-PMS-IN
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Shouyao Holdings (Beijing) Co. LTDNot yet recruiting
-
Abbisko Therapeutics Co, LtdNot yet recruiting
-
Vigonvita Life SciencesNot yet recruiting
Clinical Trials on Mucinex™ extended-release (SE)
-
ShireCompletedDiverticulitisUnited States, Italy, Germany, Canada, Brazil, Romania, Netherlands, Finland, South Africa, Hungary
-
Hangzhou Highlightll Pharmaceutical Co., LtdCompleted
-
Luye Pharma Group Ltd.Shandong Luye Pharmaceutical Co., Ltd.Completed
-
AstraZenecaWithdrawnHealthy Male Subjects | Pharmacokinetics | Safety | Food EffectUnited Kingdom
-
Abbott Medical DevicesTerminatedPersistent Atrial FibrillationTaiwan, Singapore, Korea, Republic of, Hong Kong, Thailand
-
Ultragenyx Pharmaceutical IncCompletedHereditary Inclusion Body Myopathy (HIBM)United States
-
Murdoch Childrens Research InstituteRecruitingNeoplasms | Bone Marrow TransplantationAustralia
-
Luye Pharma Group Ltd.CompletedMajor Depressive Disorder (MDD)China
-
Ultragenyx Pharmaceutical IncTerminatedHereditary Inclusion Body Myopathy | GNE Myopathy | Inclusion Body Myopathy 2 | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing MyopathyCanada, United States, Bulgaria
-
Boehringer IngelheimCompleted